NAD+ Dosage: IV & Injectable Protocols
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← NAD+ encyclopedia entry · See also: 5-Amino-1MQ dosage · Regulatory tracker
NAD+ is a coenzyme, not a peptide, included here because it travels with peptides in longevity protocols. There is no approved drug dose; "NAD+ therapy" is a wellness/research IV or injectable with very wide, non-standardized ranges. The figures below describe clinic and community practice for education — not a validated regimen or instructions for use.
The short version
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, essential to energy production and many repair processes; cellular levels decline with age, which is the rationale behind "NAD+ therapy." Because it is sold as a wellness service rather than an approved medicine, there is no single correct dose — protocols vary by clinic, route, and goal, and that variability is the most important thing to understand before reading any specific number.
How it is dosed in practice
Two delivery routes dominate, with very different feel and pacing:
| Route | Commonly reported | Notes |
|---|---|---|
| IV infusion | ~100–1000 mg per session | Slow drip; rapid infusion causes flushing/nausea/chest tightness |
| Subcutaneous | Smaller divided amounts | Used in some at-home wellness protocols |
A practical, frequently reported point: NAD+ given too quickly by IV causes uncomfortable effects — flushing, nausea, cramping, a chest-pressure sensation — which is why clinic infusions are run slowly over an extended period. The broad milligram range reflects that there is no validated target; it is set by clinic protocol and tolerance, not by approval-grade dosing studies.
NAD+ vs its precursors (NMN, NR)
Much of the consumer market is actually about precursors — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — which the body converts toward NAD+ and which are usually taken orally as supplements. These are a different proposition from injected/IV NAD+ in route, regulation, and evidence. NMN in particular has been the subject of US regulatory back-and-forth over its supplement status. If your interest is oral and convenient, the conversation is really about precursors; injectable NAD+ is the clinic-service end of the spectrum.
Status
NAD+ is not an FDA-approved drug. Injectable and IV NAD+ exist in the wellness/research space rather than as approved therapeutics, and the human evidence for the popular longevity claims is far less settled than the marketing suggests. See the Regulatory Status Tracker for context on how such products are treated.
Frequently asked questions
Why does an IV take so long?
Infusing NAD+ slowly limits the flushing, nausea, and chest-tightness that come with rapid administration; the slow drip is about tolerability.
Is oral NAD+ effective?
Oral NAD+ itself is poorly absorbed intact, which is why the supplement market focuses on precursors (NMN, NR) the body can convert — a different approach with its own evidence questions.
Are the longevity claims proven?
No. The age-related decline in NAD+ is real, but that does not establish that supplementing it produces the broad anti-aging benefits often claimed; human evidence remains limited.
Sources
- Rajman L, Chwalek K, Sinclair DA. "Therapeutic potential of NAD-boosting molecules." Cell Metab. 2018;27:529–547.
- Reviews of NAD+ precursor (NMN/NR) pharmacology and regulatory status.
Medical disclaimer: Education only, not medical advice. NAD+ is not an approved drug; dosing figures reflect wellness/community practice, not a recommendation. Consult a licensed clinician.